IDEAYA Biosciences (NASDAQ:IDYA) – Equities researchers at Oppenheimer issued their Q3 2019 earnings per share (EPS) estimates for IDEAYA Biosciences in a report released on Wednesday, October 16th. Oppenheimer analyst K. Degeeter anticipates that the company will earn ($0.68) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $17.00 target price on the stock. Oppenheimer also issued estimates for IDEAYA Biosciences’ Q4 2019 earnings at ($0.69) EPS, FY2019 earnings at ($2.79) EPS, Q1 2020 earnings at ($0.75) EPS, Q2 2020 earnings at ($0.81) EPS, Q3 2020 earnings at ($0.83) EPS, Q4 2020 earnings at ($0.87) EPS and FY2020 earnings at ($3.26) EPS.
Separately, Robert W. Baird assumed coverage on IDEAYA Biosciences in a research report on Monday, September 9th. They issued an “outperform” rating and a $30.00 price objective for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. IDEAYA Biosciences has an average rating of “Buy” and a consensus target price of $19.20.
IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Monday, August 12th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.66).
A number of large investors have recently added to or reduced their stakes in IDYA. Perceptive Advisors LLC purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $11,369,000. Laurion Capital Management LP purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $199,000. Monashee Investment Management LLC purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $354,000. Point72 Asset Management L.P. purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $1,948,000. Finally, Boxer Capital LLC purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $7,612,000. Hedge funds and other institutional investors own 25.12% of the company’s stock.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Featured Story: Cryptocurrencies
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.